Filing Flows › Spero Therapeutics (SPRO) › Q3 2025
Spero Therapeutics (SPRO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Spero Therapeutics (SPRO) reported revenue of $5.4M for the third quarter 2025 (Q3 2025), -60% from a year earlier and -62% from the quarter before. Operating margin was -145.5%, net loss $7.4M (135.6% of revenue).
Spero Therapeutics, Q3 2025: revenue $5.4M (-60% year over year), operating margin -145.5%, net loss $7.4M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.4M | -62% | -60% |
| Operating profit | −$7.9M | — | — |
| Net earnings | −$7.4M | — | — |
| Operating cash flow | $17.4M | — | +37% |
What changed
Revenue was $5.4M in Q3 2025, down 60% year over year and down 62% from the previous quarter. Collaboration Revenue Related Party was the largest line at 56% of revenue. Collaboration Revenue Related Party lost $4.7M year over year (down 61%), 59% of the total change.
Operating costs exceeded revenue by $7.9M, an operating margin of -145.5%. Total costs fell 58% while revenue fell 60%. The quarter ended with a net loss of $7.4M, wider than the previous quarter's $1.7M loss.
Operating cash flow was $17.4M (up 37% year over year). Non-cash charges added back $1.0M of share-based compensation. Working capital and other items added $23.8M.
Questions
What was Spero Therapeutics' revenue in the third quarter 2025?
Spero Therapeutics (SPRO) reported revenue of $5.4M for the third quarter 2025 (Q3 2025), -60% from a year earlier and -62% from the quarter before.
Was Spero Therapeutics profitable in the third quarter 2025?
Operating loss was $7.9M (-145.5% of revenue) and net loss $7.4M.
Source: Spero Therapeutics 10-Q on SEC EDGAR.